| Not on vitamin D or cinacalcet, by DOPPS country and cross-section |
| N Ptnts | Wgtd % | Total N | ||
|---|---|---|---|---|
| DOPPS Country | DOPPS Cross-section | 5,202 | 57.1% | 9,117 |
| All | DOPPS 2(2002) | |||
| DOPPS 3(2006) | 3,460 | 40.5% | 8,552 | |
| DOPPS 3(2007) | 2,920 | 37.9% | 7,672 | |
| AusNZ | DOPPS 2(2002) | 256 | 50.2% | 513 |
| DOPPS 3(2006) | 250 | 47.1% | 527 | |
| DOPPS 3(2007) | 180 | 38.9% | 486 | |
| Belgium | DOPPS 2(2002) | 337 | 62.8% | 538 |
| DOPPS 3(2006) | 262 | 51.8% | 509 | |
| DOPPS 3(2007) | 184 | 43.3% | 420 | |
| Canada | DOPPS 2(2002) | 295 | 50.9% | 601 |
| DOPPS 3(2006) | 249 | 45.1% | 551 | |
| DOPPS 3(2007) | 171 | 38.0% | 445 | |
| France | DOPPS 2(2002) | 303 | 56.9% | 528 |
| DOPPS 3(2006) | 303 | 54.7% | 551 | |
| DOPPS 3(2007) | 269 | 48.3% | 543 | |
| Germany | DOPPS 2(2002) | 229 | 39.9% | 571 |
| DOPPS 3(2006) | 175 | 31.2% | 583 | |
| DOPPS 3(2007) | 173 | 29.4% | 623 | |
| Italy | DOPPS 2(2002) | 367 | 63.8% | 576 |
| DOPPS 3(2006) | 245 | 45.9% | 533 | |
| DOPPS 3(2007) | 243 | 44.5% | 542 | |
| Japan | DOPPS 2(2002) | 871 | 48.3% | 1,805 |
| DOPPS 3(2006) | 775 | 42.7% | 1,832 | |
| DOPPS 3(2007) | 767 | 41.5% | 1,867 | |
| Spain | DOPPS 2(2002) | 441 | 71.7% | 613 |
| DOPPS 3(2006) | 350 | 52.8% | 666 | |
| DOPPS 3(2007) | 279 | 51.2% | 555 | |
| Sweden | DOPPS 2(2002) | 180 | 32.7% | 547 |
| DOPPS 3(2006) | 176 | 32.4% | 542 | |
| DOPPS 3(2007) | 161 | 31.2% | 511 | |
| UK | DOPPS 2(2002) | 306 | 53.3% | 565 |
| DOPPS 3(2006) | 187 | 42.1% | 445 | |
| DOPPS 3(2007) | 138 | 38.7% | 351 | |
| US | DOPPS 2(2002) | 1,617 | 71.6% | 2,260 |
| DOPPS 3(2006) | 488 | 26.4% | 1,813 | |
| DOPPS 3(2007) | 355 | 25.2% | 1,329 | |
| Medications reported as prescribed (not necessarily taken) in previous four months, among all patients |
Please see additional methodological information in the Data Sources and Methods section.